PT  - JOURNAL ARTICLE
AU  - Tobias Maurer
AU  - Markus Graefen
AU  - Henk van der Poel
AU  - Freddie Hamdy
AU  - Alberto Briganti
AU  - Matthias Eiber
AU  - Hans-Jürgen Wester
AU  - Fijs W.B. van Leeuwen
TI  - Prostate-Specific Membrane Antigen–Guided Surgery
AID  - 10.2967/jnumed.119.232330
DP  - 2020 Jan 01
TA  - Journal of Nuclear Medicine
PG  - 6--12
VI  - 61
IP  - 1
4099  - http://jnm.snmjournals.org/content/61/1/6.short
4100  - http://jnm.snmjournals.org/content/61/1/6.full
SO  - J Nucl Med2020 Jan 01; 61
AB  - Since its introduction to the diagnostic pathway for prostate cancer management, prostate-specific membrane antigen (PSMA)–ligand PET has demonstrated great potential. PSMA-ligand imaging is increasingly influencing therapeutic decision making, although its impact on patient outcomes still needs to be defined. One relatively new application, enabled through chemical and engineering efforts, is PSMA-guided surgery. This review highlights the potential of PSMA-guided surgery and discusses its implications in lymph node dissection in primary and recurrent prostate cancer.